MoneyThe story, in brief
Alphabet's Isomorphic Labs raises $2.1 billion to scale AI drug discovery toward clinical trials
$2.1B. That's what Demis Hassabis just raised to turn AI drug discovery into clinical reality.
The KeyNews take
Why it matters
Isomorphic Labs' Series B signals that AI-driven drug discovery is moving from research benchmark wins to real-world pharmaceutical deployment—a watershed moment for AI's utility in life sciences and a test of whether DeepMind's research prowess translates to biotech ROI.
The key facts
6 to knowIsomorphic Labs closes $2.1B Series B
Led by Thrive Capital
Founded by Demis Hassabis (DeepMind co-founder)
Funding targets IsoDDE platform expansion
Goal: advance drug candidates to clinical trials
Alphabet subsidiary
Go to the source
The Decoderthe-decoder.com
Publisher excerpt: Isomorphic Labs, the AI drug research company led by DeepMind co-founder Demis Hassabis, has closed a $2.1 billion Series B round led by Thrive Capital. The funding will go toward expanding its in-house platform IsoDDE and advancing drug candidates toward clinical trials.